505(b)(2) formulation for the treatment of chemotherapy induced nausea and vomiting. Multiple advantages over currently available products including the ability to use without further reconstitution.
About Jim Usry
This author has yet to write their bio.
Meanwhile lets just say that we are proud Jim Usry contributed a whooping 13 entries.
505(b)(2) formulation for schizophrenia available for in-licensing:
Oral Solid Dose (OSD) Tablets & Capsules facility, 45 minutes from Boston, with $20 million in facility value / equipment. Asset Overview Opportunity
University-owned high-throughput, nanoparticle processing technology company. Continuous Manufacturing of Nanomedicines:
Ready for Immediate Acquisition
Self-amplifying RNA (saRNA) Virtual Biotech seeks VC investment to develop a pipeline of RNA therapeutics and vaccines.
Private-Equity owned, Phase III plasma-derived therapeutic company is ready to build the commercial facility with One Million Liter annual capacity, in Dallas Texas Looking to Raise Capital
Non-cGMP API Drug Development Starting Materials + API Pilot
Plant and cGMP CDMO: Ready for Immediate Acquisition with operations in Jaipur, India and Birmingham, Alabama
Approved 505(b)(2) available for in-licensing:
CHP is pleased to announce the availability of an approved 505(b)(2) product in the cardiovascular space. US rights only.
Marketed product in the GI space (idiopathic bowel syndrome, diarrhea, opioid induced constipation) available for acquisition. Client will also consider a distribution partnership.
Buy side client seeks to acquire manufacturing facilities in the US. Sterile manufacturing capabilities highly desired.